Treatment of acute renal failure with urodilatin after unrelated bone marrow transplantation in an 18-month-old boy.
Acute renal failure was imminent in an 18-month-old male infant 20 days after unrelated BMT. The infant was treated with urodilatin (URO), a natriuretic vasorelaxant peptide. Diuresis increased 2 h after the commencement of URO infusion and the furosemide infusion was reduced from 5 mg/h to 2.5 mg/h. After seven days of URO treatment diuresis was normal, the serum creatinine level had decreased, and furosemide was reduced from 12 mg/kg bw/d to 1.8 mg/kg bw/d. No side effects were observed either during or following URO therapy. We consider URO to be a promising drug for the treatment, without any apparent side effects, of imminent or manifest acute renal failure in infants following BMT.
Laws
H J
HJ
Department of Paediatric Haematology and Oncology, Heinrich-Heine University, Düsseldorf, FRG.
Kropp
S
S
Meyer
M
M
Forssmann
W G
WG
Burdach
S
S
D058186:Acute Kidney Injury / Q000188:drug therapy*; D009320:Atrial Natriuretic Factor / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D016572:Cyclosporine / Q000009:adverse effects; D004232:Diuretics / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D008297:Male; D010446:Peptide Fragments / Q000627:therapeutic use*
D004232:Diuretics; D010446:Peptide Fragments; C056452:Ularitide; D016572:Cyclosporine; D009320:Atrial Natriuretic Factor